ArticleOncoimmunology

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.

Thilo Gambichler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.